Structure Database (LMSD)

LM_ID Common Name Systematic Name Main class Sub class Mass Formula
LMFA04010481 13-epi-10-J4-NeuroP (S,4Z,7Z,11E)-10-hydroxy-12-((1R,5S)-4-oxo-5-((Z)-pent-2-en-1-yl)cyclopent-2-en-1-yl)dodeca-4,7,11-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010427 13-epi-13-A4-NeuroP (R,4Z,7Z,10Z,14E)-15-((1R,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010207 13-epi-13-D4c-NeuroP (R,4Z,7Z,10Z,14E)-15-((1R,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010210 13-epi-13-D4t-NeuroP (R,4Z,7Z,10Z,14E)-15-((1S,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010335 13-epi-13-E4c-NeuroP (R,4Z,7Z,10Z,14E)-15-((1R,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010338 13-epi-13-E4t-NeuroP (R,4Z,7Z,10Z,14E)-15-((1S,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010079 13-epi-13-F4c-NeuroP (R,4Z,7Z,10Z,14E)-15-((1R,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010082 13-epi-13-F4t-NeuroP (R,4Z,7Z,10Z,14E)-15-((1S,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010491 13-epi-13-J4-NeuroP (R,4Z,7Z,10Z,14E)-15-((1S,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010457 13-epi-20-A4-NeuroP (4Z,7Z,10Z)-12-((1S,2R)-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopent-3-en-1-yl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010265 13-epi-20-D4c-NeuroP (4Z,7Z,10Z)-12-((1S,2S,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010264 13-epi-20-D4t-NeuroP (4Z,7Z,10Z)-12-((1R,2R,5S)-5-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-3-oxocyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010393 13-epi-20-E4c-NeuroP (4Z,7Z,10Z)-12-((1S,2S,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010392 13-epi-20-E4t-NeuroP (4Z,7Z,10Z)-12-((1R,2R,3R)-3-hydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)-5-oxocyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010137 13-epi-20-F4c-NeuroP (4Z,7Z,10Z)-12-((1S,2S,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010136 13-epi-20-F4t-NeuroP (4Z,7Z,10Z)-12-((1R,2R,3R,5S)-3,5-dihydroxy-2-((S,E)-3-hydroxypent-1-en-1-yl)cyclopentyl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010521 13-epi-20-J4-NeuroP (4Z,7Z,10Z)-12-((1R,5S)-5-((S,E)-3-hydroxypent-1-en-1-yl)-4-oxocyclopent-2-en-1-yl)dodeca-4,7,10-trienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010439 14-A4-NeuroP (Z)-6-((1R,2R)-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010231 14-D4c-NeuroP (Z)-6-((1R,2S,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010234 14-D4t-NeuroP (Z)-6-((1S,2R,5S)-5-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010359 14-E4c-NeuroP (Z)-6-((1R,2S,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010362 14-E4t-NeuroP (Z)-6-((1S,2R,3R)-3-hydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010528 14-F3t-NeuroP-DPAomega-3 1a,1b-dihomo-8S,10R,14S-trihydroxy-12E,16Z,19Z-prostatrienoic acid-cyclo[7S,11R] Docosanoids [FA04] Neuroprostanes [FA0401] 380.26 C22H36O5
LMFA04010004 14-F4-NeuroP (Z)-6-(3,5-dihydroxy-2-((1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010103 14-F4c-NeuroP (Z)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010106 14-F4t-NeuroP (Z)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010503 14-J4-NeuroP (Z)-6-((1S,5S)-5-((S,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010435 14-epi-14-A4-NeuroP (Z)-6-((1R,2R)-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopent-3-en-1-yl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010227 14-epi-14-D4c-NeuroP (Z)-6-((1R,2S,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010230 14-epi-14-D4t-NeuroP (Z)-6-((1S,2R,5S)-5-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-3-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010355 14-epi-14-E4c-NeuroP (Z)-6-((1R,2S,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010358 14-epi-14-E4t-NeuroP (Z)-6-((1S,2R,3R)-3-hydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-5-oxocyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010099 14-epi-14-F4c-NeuroP (Z)-6-((1R,2S,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010102 14-epi-14-F4t-NeuroP (Z)-6-((1S,2R,3R,5S)-3,5-dihydroxy-2-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)cyclopentyl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010499 14-epi-14-J4-NeuroP (Z)-6-((1S,5S)-5-((R,1E,5Z,8Z)-3-hydroxyundeca-1,5,8-trien-1-yl)-4-oxocyclopent-2-en-1-yl)hex-4-enoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010433 16-epi-13-A4-NeuroP (S,4Z,7Z,10Z,14E)-15-((1S,2R)-2-ethyl-5-oxocyclopent-3-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010217 16-epi-13-D4c-NeuroP (S,4Z,7Z,10Z,14E)-15-((1S,2S,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010216 16-epi-13-D4t-NeuroP (S,4Z,7Z,10Z,14E)-15-((1R,2R,5S)-2-ethyl-5-hydroxy-3-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010345 16-epi-13-E4c-NeuroP (S,4Z,7Z,10Z,14E)-15-((1S,2S,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010344 16-epi-13-E4t-NeuroP (S,4Z,7Z,10Z,14E)-15-((1R,2R,3R)-2-ethyl-3-hydroxy-5-oxocyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010089 16-epi-13-F4c-NeuroP (S,4Z,7Z,10Z,14E)-15-((1S,2S,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010088 16-epi-13-F4t-NeuroP (S,4Z,7Z,10Z,14E)-15-((1R,2R,3R,5S)-2-ethyl-3,5-dihydroxycyclopentyl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010497 16-epi-13-J4-NeuroP (S,4Z,7Z,10Z,14E)-15-((1R,5S)-5-ethyl-4-oxocyclopent-2-en-1-yl)-13-hydroxypentadeca-4,7,10,14-tetraenoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010447 17-A4-NeuroP (4Z,7Z)-9-((1R,2R)-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopent-3-en-1-yl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 358.21 C22H30O4
LMFA04010247 17-D4c-NeuroP (4Z,7Z)-9-((1R,2S,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010250 17-D4t-NeuroP (4Z,7Z)-9-((1S,2R,5S)-5-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-3-oxocyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010375 17-E4c-NeuroP (4Z,7Z)-9-((1R,2S,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010378 17-E4t-NeuroP (4Z,7Z)-9-((1S,2R,3R)-3-hydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)-5-oxocyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 376.22 C22H32O5
LMFA04010002 17-F4-NeuroP (4Z,7Z)-9-(3,5-dihydroxy-2-((1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5
LMFA04010119 17-F4c-NeuroP (4Z,7Z)-9-((1R,2S,3R,5S)-3,5-dihydroxy-2-((S,1E,5Z)-3-hydroxyocta-1,5-dien-1-yl)cyclopentyl)nona-4,7-dienoic acid Docosanoids [FA04] Neuroprostanes [FA0401] 378.24 C22H34O5